High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features  by Sun, Ping-Li et al.
ORIGINAL ARTICLE
High Incidence of EGFR Mutations in Korean Men Smokers
with No Intratumoral Heterogeneity of Lung
Adenocarcinomas
Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions,
and Clinical Features
Ping-Li Sun, MD,*† Hyesil Seol, MD,‡ Hyun Ju Lee, MD,§ Seol Bong Yoo, MD,* Hyojin Kim, MD,*
Xianhua Xu, MD,* Sanghoon Jheon, MD, PhD,† Choon-Taek Lee, MD, PhD,
Jong-Suk Lee, MD, PhD, and Jin-Haeng Chung, MD, PhD*
Introduction: Epidermal growth factor receptor (EGFR) mutation
has been known to be associated with adenocarcinoma with bron-
chioloalveolar carcinoma (BAC; lepidic) feature. This study was
aimed to characterize the frequency of EGFR mutations and their
association with histologic subtypes in Korean nonsmall cell lung
cancer (NSCLC) patients.
Methods: Three hundred eighty-two (88 biopsies and 294 resec-
tions) NSCLC patients were investigated for EGFR mutations (ex-
ons 18–21) by polymerase chain reaction and direct sequencing
method. For the resected adenocarcinoma specimens, histologic
subtypes were classified according to both 2004 World Health
Organization classification and 2011 International Association for
the Study of Lung Cancer/American Thoracic Society/European
Respiratory Society classification. The results were correlated with
EGFR mutation and clinicopathologic features.
Results: EGFR mutations were detected in 196 of 382 NSCLCs
(51.3%) and were more frequent in women than in men (65.7%
versus 34.3%, p  0.001) and in nonsmokers than in smokers
(63.4% versus 32.0%, p  0.001). Regarding histologic subtypes of
adenocarcinoma, mixed acinar and BAC pattern showed the most
frequent EGFR mutation (67.6%), followed by mixed papillary and
acinar (65.2%), mixed solid and acinar (38.2%), micropapillary and
acinar (30.4%), and acinar and mucinous BAC (13.3%). In addition,
EGFR mutations were more frequently observed in tumors with BAC
or papillary components than those with mucinous BAC or solid
components. Identical EGFR mutations were detected in a single tumor
showing mixed histological features. EGFR protein expression was
seen more frequently in tumors with EGFR mutations than those without
EGFR mutations (75.3% versus 24.7%, p 0.003).EGFRmutations were
significantly more common in tumors with thyroid transcription factor-1
(TTF-1) expression than those without TTF-1 (p 0.001), and almost all
(92.7%) mutated adenocarcinomas were TTF-1 positive.
Conclusions: The incidence of EGFR mutations is variable according
to histologic subtypes, gender, and smoking history. The mixed acinar
and BAC and papillary and acinar subtypes, the presence of BAC
(lepidic) or papillary components, EGFR, and TTF-1 protein expression
can predict higher EGFR mutation in lung adenocarcinoma. However,
intratumoral heterogeneity of EGFR mutation was not found. In addi-
tion, relatively high incidence of EGFR mutations in Korean men who
smoked with adenocarcinoma histology suggests that these patients
should not be left behind EGFR mutation test.
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Lung cancer is the leading cause of cancer death worldwide,1and the incidence of adenocarcinoma of the lung is increas-
ing.2 It is well known that pulmonary adenocarcinomas show a
wide variety of histologic features such as papillary, acinar
(tubular), solid, bronchioloalveolar carcinoma (BAC; lepidic),
and mucin-producing elements. Indeed, the 2004 World Health
Organization (WHO) classifications admit “most adenocarcino-
mas will be of the mixed subtype.”3,4 However, the reproduc-
ibility of recognizing histologic subtypes is very low and the
new lung adenocarcinoma classification by International Asso-
ciation for the Study of Lung Cancer (IASLC)/American Tho-
racic Society(ATS)/European Respiratory Society (ERS) pro-
posed that the term “mixed subtype adenocarcinoma” is no
longer used for invasive adenocarcinomas, comprehensive his-
tologic subtyping used to assess histologic patterns semiquanti-
tatively in 5% increments, choosing a single predominant pat-
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tern. Individual tumors are then classified according to the
predominant pattern, and the percentages of the subtypes are
additionally reported.5
The presence of epidermal growth factor receptor (EGFR)
mutations in a subset of adenocarcinomas is the best predictor of
response to EGFR tyrosine kinase inhibitors (TKIs).6–11 There
have been many previous reports regarding the association
between EGFR mutations and specific subtypes of adenocarci-
noma such as BAC (lepidic), papillary, and micropapillary
patterns. Therefore, these findings have raised the fundamental
questions: “Does morphology reflect molecular alterations (such
as EGFR mutation)?” and “Is there an intratumoral hetero-
geneity of EGFR mutation in the mixed subtype of ade-
nocarcinoma?” A large number of studies have focused on
the pathologic features of tumors harboring EGFR muta-
tions to evaluate the predictive significance of morpho-
logic characterization. Adenocarcinoma associated with
features of lepidic growth pattern (formerly BAC) is
known to have frequent EGFR mutations and potentially
sensitive to EGFR-TKIs.7–9,12,13 Yatabe et al.14,15 described a
terminal respiratory unit-type adenocarcinoma with thyroid
transcription factor-1 (TTF-1) expression, representing a dis-
tinct subset significantly related to EGFR mutations. Some
studies in which the histologic-genetic correlations were
analyzed reported that the positive histologic-molecular cor-
relation was also observed between EGFR mutations and the
papillary, acinar, and/or micropapillary subtypes.8,10,13,16 On
the contrary, negative correlations were identified between
EGFR mutations and solid and/or mucinous BAC features of
adenocarcinoma.17,18 However, the available data are partly
discordant, and the correlation between EGFR mutations and
each histologic subtype has not been clearly established in the
Korean NSCLCs according to both 2004 WHO classification
and new IASLC/ATS/ERS classification.
In addition, correlation between EGFR gene mutation
and protein expression assessed by immunohistochemistry
(IHC) are still controversial. Although EGFR mutation is
known to be strongly associated with TTF-1expression,14,15
the association between EGFR mutation and EGFR protein is
not clear. EGFR protein expression profiles in NSCLC
showed a wide range of results (16–80%), which might be
due to the interlaboratory differences in the antibody clones
used, preanalytical variables, and laboratory methods.19–21
In this study, we evaluated the following: (1) correla-
tion between histologic subtypes of adenocarcinoma and
EGFR mutations using both 2004 WHO classification and
new IASLC/ATS/ERS classification, (2) mapping of EGFR
mutation in the individual tumor showing various histologic
subtypes, (3) clinicopathologic characteristics of NSCLCs
harboring EGFR mutations, and (4) correlation between
EGFR mutations and EGFR and TTF-1 protein expressions.
PATIENTS AND METHODS
Patients and Specimens
Three hundred eighty-two NSCLC specimens (88 biopsy
and 294 resection samples) diagnosed at Seoul National Univer-
sity Bundang Hospital from 2006 to 2010 were included in this
study. The 382 patients included 175 men and 207 women with
an average age of 62.8 years (median, 64.5 years; range, 26–91
years). Clinicopathologic informations were obtained from the
medical records and pathology reports. The patients’ character-
istics are shown in Table 1. This study was approved by
institutional review board. The hematoxylin and eosin-stained
slides of the specimens were reviewed independently by two
TABLE 1. Relationship between EGFR Mutations and
Clinicopathologic Factors
Characteristics
Examined
No. (%)
EGFR Mutation
Status
p
Positive
(%)
Negative
(%)
Total 382 (100.0) 196 (51.3) 186 (48.7)
Age (yr; mean) 62.8 63.0 62.6
Sex
Men 175 (45.8) 60 (34.3) 115 (65.7) 0.001
Women 207 (54.2) 136 (65.7) 71 (34.3)
Smoking status
Nonsmoker 235 (61.5) 149 (63.4) 86 (36.6) 0.001
Smoker 147 (38.5) 47 (32.0) 100 (68.0)
Former 82 30 (36.6) 52 (63.4) 0.18
Current 65 17 (26.2) 48 (73.8)
Sex, smoking, and
histology
Men, nonsmoker 44 (25.1) 22 (50.0) 22 (50.0)
Men, nonsmoker,
and ADC
44 22 (50.0) 22 (50.0)
Men, smoker 131 (74.9) 38 (29.0) 93 (71.0)
Men, smoker,
and ADC
118 35 (29.7) 83 (70.3)
Women, nonsmoker 191 (92.3) 127 (66.5) 64 (33.5)
Women, nonsmoker,
and ADC
181 124 (68.5) 57 (31.5)
Women, smoker 16 (7.7) 9 (56.3) 7 (43.7)
Women, smoker,
and ADC
15 9 (60.0) 6 (40.0)
Histological diagnosis 0.008a
Total NSCLCs 382 (100.0) 196 (51.3) 186 (48.7)
ADC 358 (93.7) 190 (53.1) 168 (46.9)
Other NSCLCs 24 (6.3) 6 (25.0) 18 (75.0)
Sampling methods
Biopsy 88 (23.0) 48 (54.5) 40 (45.5)
ADC 79 44 (55.7) 35 (44.3)
Other NSCLCs 9 4 (33.3) 5 (66.7)
Resection 294 (77.0) 148 (50.3) 146 (49.7)
ADC 279 146 (52.3) 133 (47.7) 0.001b
Mixed ADC 249 (89.2) 138 (55.4) 111 (44.6)
Pure ADC 30 (10.8) 8 (26.7) 22 (73.3)
Acinar 18 7 (38.9) 11 (61.1)
Papillary 3 1 (33.3) 2 (66.7)
Solid 7 0 (0) 7 (100.0)
Mucinous 2 0 (0) 2 (100.0)
Other NSCLCs 15 2 (13.3) 13 (86.7)
a ADC vs. other NSCLCs.
b Mixed ADC vs. pure ADC.
ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; EGFR, epidermal
growth factor receptor.
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pathologists (P.S. and J.H.C.), and the consensus was made by
repeated examination when discordance was present for the
diagnosis and/or subtype classification. The histopathological
classification of the specimens was done based on both 2004
WHO classification system3 and new adenocarcinoma classifi-
cation by IASLC/ATS/ERS.5 The 294 resected NSCLCs were
composed of 279 adenocarcinomas (249 mixed subtype and 30
pure subtype) and 15 other NSCLCs (8 adenosquamous carci-
nomas, 3 squamous cell carcinomas, 2 pleomorphic carcinomas,
and 2 large cell neuroendocrine carcinomas). The histologic
features of 249 mixed subtype adenocarcinomas were evaluated
based on either the two major components or the presence of
acinar, BAC, papillary, micropapillary, mucinous BAC, and
solid components using the 2004 WHO classification system.3
According to the two major components of the mixed subtype
adenocarcinoma, the tumors were subdivided into six patterns:
(1) mixed acinar and BAC pattern (AB); (2) mixed solid and
acinar pattern (SA); (3) mixed papillary and acinar pattern (PA);
(4) mixed micropapillary and acinar pattern (MPA); (5) mixed
acinar and mucinous BAC pattern (AmB); and (6) other patterns
(including four solid and mucinous BAC, six papillary and
nonmucinous BAC, three micropapillary and nonmucinous
BAC, four papillary and micropapillary, one acinar and signet
ring cell, three solid and papillary, and two papillary and muci-
nous BAC) (Figures 1A–E). Next, we further classified resected
adenocarcinomas based on the predominant pattern, i.e., lepidic
growth pattern (formerly BAC), acinar, papillary, micropapil-
lary, and solid components according to the new IASLC/ATS/
ERS adenocarcinoma classification.
EGFR Mutational Analysis
EGFR mutations at exon 18–21 were examined by poly-
merase chain reaction and direct DNA sequencing method as
described previously.22 Genomic DNA was extracted from par-
affin-embedded tissue. After deparaffinization with xylene, tis-
sue sections were stained with hematoxylin and eosin, and target
lesions were selectively dissected to minimize any normal tissue.
To investigate intratumoral heterogeneity of EGFR mutation in
the mixed subtype of adenocarcinomas, we selected 23 forma-
lin-fixed paraffin-embedded tissues from 10 adenocarcinoma
cases showing mixed subtype. In each case, two or three areas
showing different growth pattern were selected and carefully
dissected for an EGFR mutation analysis (Table 2).
EGFR and TTF-1 IHC
Among the 382 cases, 243 specimens were evaluated
for the expression of EGFR protein and 190 for the expres-
sion of TTF-1 protein by IHC. The results of EGFR and
TTF-1 IHC staining were reported as a semiquantitative
scoring system based on the percentage of stained cells and
staining intensity as described previously.20 The staining
intensity of tumor cells was graded as weak (1), moderate
(2), or strong (3). Modified Colorado scoring was per-
formed by multiplying the percentage of positive cells (0–
100%) and staining intensity (1–3) and then assigned to
grade 1 (score 0–100), grade 2 (101–200), and grade 3
(201–300). The tumors with grade 2 or 3 IHC staining were
considered as positive for EGFR or TTF-1 expression.
Statistical Analysis
Statistical analyses were performed using Fisher’s ex-
act test or 2 test and Spearman’s correlation analysis. Sta-
tistical significance was determined by a two-tailed p value
less than 0.05.
RESULTS
Histopathological Features According to both
2004 WHO Classification and IASLC/ATS/ERS
Classification
Of the 382 tumors (88 biopsy and 294 resection samples),
358 were adenocarcinomas and 24 were other NSCLCs. The
FIGURE 1. Histologic features of
adenocarcinoma mixed subtype. A,
Mixed acinar and bronchioloalveolar
pattern. B, Mixed solid and acinar
pattern. C, Mixed papillary and aci-
nar pattern. D, Mixed micropapillary
and acinar pattern. E, Mixed acinar
and mucinous bronchioloalveolar
pattern.
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294 resection samples consisted of 279 adenocarcinomas (249
mixed subtype [89.2%] and 30 pure subtype [10.8%]) and 15
other NSCLCs according to 2004 WHO classification. Regard-
ing the mixed subtype of adenocarcinoma, the most common
histologic pattern more than 5% in the tumor was acinar (91.6%,
228 of 249), followed by micropapillary (56.2%, 140 of 249),
BAC (lepidic growth) (47%, 117 of 249), papillary (24.1%, 60
of 249), solid (16.5%, 41 of 249), and mucinous BAC (6.4%,
16 of 249). The classification based on the two major compo-
nents of the resected adenocarcinoma indicated that the most
common mixed subtype was AB (43.4%, 108 of 249) followed
by PA (18.5%, 46 of 249), SA (13.7%, 34 of 249), MPA (9.2%,
23 of 249), other patterns (9.2%, 23 of 249), and AmB (6.0%, 15
of 249) (Table 3).
When classifying the all resected adenocarcinoma
based on the major histologic component according to the
new adenocarcinoma classification,5 the most common sub-
type was acinar (68.5%, 191 of 279), followed by papillary
(11.8%, 33 of 279), solid (9.0%, 25 of 279), lepidic growth
pattern (formerly BAC) (7.5%, 21 of 279), micropapillary
(1.4%, 4 of 279), and invasive mucinous adenocarcinoma
(formerly mucinous BAC) (1.8%, 5 of 279).
Incidence of EGFR Mutation in Korean NSCLC
According to Clinicopathologic Characteristics
A total of 382 NSCLCs were examined for EGFR
mutations in the exons 18 to 21 of the EGFR gene by
polymerase chain reaction and direct DNA sequencing. The
overall frequency of EGFR mutation was found in 51.3%
(196 of 382) of the NSCLC. Seven patients had mutations in
the multiple sites (three patients in the exons 18 and 21, two
patients in the exons 18 and 20, and two in exons 20 and 21,
respectively). The most common mutation was missense
mutation (L858R) in the exon 21 (96 of 203, 47.3%), and the
in-frame deletion in the exon 19 (80 of 203, 39.4%) was the
second most common type. The site of EGFR mutation was
not associated with sex, smoking status, or histological diag-
nosis. The mutation patterns of these 196 patients are sum-
marized in Table 4.
EGFR mutations were more frequent in adenocarcino-
mas than in other NSCLCs (53.1% versus 25.0%, p 0.008),
in women than in men (65.7% versus 34.3%, p 0.001), and
in nonsmokers than in smokers (63.4% versus 32.0%, p 
0.001). The frequency of EGFR mutation was enriched up to
68.5% (124 of 181) in women, nonsmokers, and adenocarci-
noma histology. The frequency of EGFR mutations was not
different according to the sampling types, i.e., surgically
resected tumor specimens versus small biopsy specimens
(p  0.05).
Significant number of men and ever-smoker patients
showed EGFR mutations (34.3%, 60 of 175, and 32.0%, 47 of
147, respectively). The incidence of EGFR mutations in men
who smoked with adenocarcinomas was 29.7% (35 of 118).
We also examined the relationship between EGFR muta-
tions and detailed smoking status in the ever-smokers (current
and former smokers); however, there was no significant differ-
ence between these two groups (p  0.18; Table 1).
Incidence of EGFR Mutation According to the
Subtypes of the Resected Adenocarcinomas
EGFR mutations were more frequently found in the
mixed subtype than in pure subtype (55.4% versus 26.7%,
p  0.001) and in adenocarcinoma with BAC component
TABLE 2. Patients Characteristics for Intratumoral Heterogeneity of EGFR Mutation Analysis
Case No. Gender Age (yr) Adenocarcinoma, Mixed Subtype EGFR Mutation Subtypes Analyzed
P 78 F 42 Papillary  acinar 2573 T G 2
P 85 M 68 Papillary  acinar Wild type 2
P 176 M 60 Solid  acinar 2573 T G 2
P 145 M 73 Solid  acinar  BAC Wild type 3
P 86 F 31 Acinar  BAC del 2235–2249 2
P 116 F 59 Acinar  BAC del 2235–2249 2
P 148 F 56 Acinar  BAC  micropapillary 2573 T G 3
P 155 F 61 Acinar  micropapillary del 2236–2250 2
P 141 F 68 Papillary  BAC 2573 T G 2
P 151 F 58 Acinar  mucinous BAC  micropapillary 2573 T G 3
EGFR, epidermal growth factor receptor; BAC, bronchioloalveolar carcinoma.
TABLE 3. EGFR Mutation of Mixed ADCs in the Resection
According to 2004 WHO Classification
Subclassification of
Mixed Type ADC No. (%)
EGFR Mutation
Status
p
Positive
(%)
Negative
(%)
Total 249 (100.0) 138 (55.4) 111 (44.6) 0.001a
Acinar  BAC 108 (43.4) 73 (67.6) 35 (32.4) 0.85b
Papillary  acinar 46 (18.5) 30 (65.2) 16 (34.8)
Solid  acinar 34 (13.7) 13 (38.2) 21 (61.8)
Micropapillary  acinar 23 (9.2) 7 (30.4) 16 (69.6)
Acinar  mucinous BAC 15 (6.0) 2 (13.3) 13 (86.7)
Other patterns 23 (9.2) 13 (56.5) 10 (43.5)
a 2 test. Other patterns: concludes four solid and mucinous, six papillary and
nonmucinous BAC, three micropapillary and nonmucinous BAC, four papillary and
micropapillary, one acinar and signet ring cell, three solid and papillary, two papillary
and mucinous BAC.
b Acinar  BAC vs. papillary  acinar, p  0.85.
EGFR, epidermal growth factor receptor; ADC, adenocarcinoma; BAC, bronchi-
oloalveolar carcinoma.
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(68.4% versus 43.9%, R  0.25, p  0.001) or papillary
components (68.3% versus 51.3%, R  0.15, p  0.02) than
in adenocarcinomas without these components. On the con-
trary, EGFR mutations were less frequently observed in
tumors with mucinous BAC (12.5% versus 58.4%, R 
0.23, p  0.001) and solid components (36.6% versus
59.1%, R  0.17, p  0.007) than in adenocarcinomas
without these components (Table 5). Regarding mixed sub-
type of adenocarcinomas, AB pattern showed the most fre-
quent EGFR mutation (67.6%, 73 of 108) followed by PA
TABLE 4. EGFR Mutation Profile in Korean Non-Small Cell Lung Cancers
Exon Alteration Nucleotide Alteration Amino Acid Alteration No. (%)
18 Substitution 2120 T G, 2156 G C L707W, G719A 1 (0.5)
18 and 21 Substitution 2125 G A, 2573 T G E709K, L858R 1 (0.5)
18 Deletion 2127–2129 del E709_T710 del, ins D 1 (0.5)
18 Substitution 2155 G A G719S 1 (0.5)
18 and 21 Substitution 2155 G A, 2582T A G719S, L861E 1 (0.5)
18 and 20 Substitution 2155 G A, 2303 G T G719S, S768I 1 (0.5)
18 Substitution 2156 G C G719A 1 (0.5)
18 and 20 Substitution 2156 G A, 2327 G A G719A, R776H 1 (0.5)
18 and 21 Substitution 2174 C T, 2573 T G T725M, L858R 1 (0.5)
19 Deletion 2235–2249 del E746_A750 del 33 (16.8)
Deletion 2235–2251 del Frameshift mutation 1 (0.5)
Deletion 2236–2244 del E746_R748 del 1 (0.5)
Deletion 2236–2250 del E746_A750 del 17 (8.7)
Deletion 2236–2254 del Frameshift mutation 2 (1.0)
Deletion 2237–2248 del, ins CAC E746_A750del, ins Ap 1 (0.5)
Deletion 2237–2251 del E746_T751del, ins A 1 (0.5)
Deletion 2237–2255 del E746_S752del, ins V 1 (0.5)
Deletion 2237–2257 del E746_P753del, ins A 1 (0.5)
Deletion 2238–2256 del Frameshift mutation 1 (0.5)
Deletion 2239–2247 del L747_E749 del 1 (0.5)
Deletion 2239–2248 del, ins C L746_A750 del, ins P 3 (1.5)
Deletion 2239–2251 del Frameshift mutation 3 (1.5)
Deletion 2239–2253 del L747_T751 del 1 (0.5)
Deletion 2239–2256 del L747_ S752 del 3 (1.5)
Deletion 2239–2263 del L747_ A755 del 1 (0.5)
Deletion 2240–2254 del L747_ T751 del 1 (0.5)
Deletion 2240–2257 del L747_ P753 del, ins S 5 (2.6)
Deletion 2240–2259 del Frameshift mutation 1 (0.5)
Deletion 2252–2276 del T751_I759 del 1 (0.5)
Deletion 2253–2276 del S752_I759 del 1 (0.5)
20 Insertion 2310–2311 ins GGT D770_N771 ins G 1 (0.5)
Deletion 2315–2320 del, ins CGG H773 del 1 (0.5)
Deletion 2311–2312 del, ins GGGTT N771 del, ins GF 1 (0.5)
Duplication dup 2284–2290 GAAGCCT Frameshift mutation 1 (0.5)
Duplication dup 2297–2305 TGGCCAGCG A767_S768 ins SVA 1 (0.5)
Duplication dup 2297–2306 TGGCCAGCGT Frameshift mutation 1 (0.5)
Duplication dup 2300–2308 CCAGCGTGG V769_D770 ins ASV 2 (1.0)
Duplication dup 2303–2311 GCGTGGACA A767_S768 ins SVD 1 (0.5)
Duplication dup 2311–2319 AACCCCCAC D770_N771 ins NPH 1 (0.5)
Duplication dup 2313–2324 CCCCCACGTGTG N771_P772 ins PHVC 1 (0.5)
Duplication dup 2316–2321 CCACGT H773_V774 ins VH 4 (2.0)
20 and 21 Substitution 2302–2303 AG CT, 2573 T G S768L, L858R 1 (0.5)
20 and 21 Substitution 2369 C T, 2573 T G T790M, L858R 1 (0.5)
21 Substitution 2497 T G, 2573 T G L833V, L858R 2 (1.0)
Substitution 2500 G C, 2573 T G V834L, L858R 1 (0.5)
Substitution 2573 T G L858R 84 (42.9)
Substitution 2573–2574 TG GT L858R 2 (1.0)
Substitution 2587 G T G863C 1 (0.5)
Total 196 (100.0)
EGFR, epidermal growth factor receptor; Ins, insertion; Del, deletion; Dup, duplication.
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(65.2%, 30 of 46), SA (38.2%, 13 of 34), MPA (30.4%, 7 of
23), and AmB patterns (13.3%, 2 of 15) (Table 3).
When classifying the tumors based on the predominant
pattern using the new adenocarcinoma IASLC/ATS/ERS
classification, the papillary predominant adenocarcinoma
showed more frequent EGFR mutation of 70.0% (21 of 30)
compared with 56.6% (98 of 173) in acinar predominant,
50.0% (2 of 4) in micropapillary predominant, 42.9% (9 of
21) in lepidic predominant (formerly nonmucinous BAC
pattern, with 5-mm invasion), 38.9% (7 of 18) in solid
predominant, and 33.3% (1 of 3) in invasive mucinous
adenocarcinoma (formerly mucinous BAC). Although the
frequency of EGFR mutation was higher in the papillary and
acinar predominant adenocarcinomas than in solid predomi-
nant and invasive mucinous adenocarcinomas, it was not
statistically significant (p  0.06) (Table 6).
Identical EGFR Mutation Status in a Mixed
Subtype of Adenocarcinoma
Ten mixed subtype adenocarcinomas were analyzed for
intratumoral heterogeneity of EGFR mutation status (Table
2). Three or two areas of the major components of each
individual tumor were selected and examined for their EGFR
mutation status. All the three or two areas showed the same
EGFR mutation status.
Association between EGFR Mutation and EGFR/
TTF-1 Protein Expression
EGFR expression was seen more frequently in tumors
with EGFR mutations than in tumors without EGFR muta-
tions (75.3% versus 24.7%, p  0.003). EGFR mutations
were significantly more common in tumors with TTF-1 ex-
pression than in those without TTF-1 expression (p 0.001).
Most of the EGFR-mutated adenocarcinomas (92.7%) were
TTF-1 positive (Table 7).
DISCUSSION
In this study, the incidence of EGFR mutations in
Korean patients with NSCLC was 51.3% (196 of 382) and
EGFR mutation was enriched up to 68.5% in women, non-
smokers with adenocarcinoma. This high prevalence of
EGFR mutations was consistent with previous reports from
the east Asian countries, but the frequency of EGFR muta-
tions in Korean NSCLCs (a single institute, Seoul National
University Bundang Hospital data) seemed to be higher than
in Japanese or Chinese patients (26–48%).12,17,23–25 Further-
more, our study showed that a significant portion of the
EGFR-mutated cases were found in men (34.3%, 60 of 175),
current or former smokers (32%, 47 of 147), and men who
smoked with adenocarcinoma (29.7%, 35 of 118). The higher
incidence of EGFR mutation in Korean men who smoked
with adenocarcinoma compared with other reports might be
due to (1) racial differences and (2) inclusion of many
nonselected and surgically resected adenocarcinomas of the
screened patients. Although the relatively high EGFR muta-
TABLE 6. EGFR Mutation of Mixed ADCs in the Resection
by New IASLC/ATS/ERS Classification
Subclassification of
Invasive ADC No. (%)
EGFR Mutation
Status
p
Positive
(%)
Negative
(%)
Total 249 (100.0) 138 (55.4) 111 (44.6) 0.06a
Acinar predominant 173 (69.5) 98 (56.6) 75 (43.4)
Papillary predominant 30 (12.0) 21 (70.0) 9 (30.0)
Lepidic predominant 21 (8.4) 9 (42.9) 12 (57.1)
Solid predominant 18 (7.2) 7 (38.9) 11 (61.1)
Micropapillary predominant 4 (1.6) 2 (50.0) 2 (50.0)
Invasive mucinous ADC 3 (1.2) 1 (33.3) 2 (66.7)
a 2 test. Papillary and acinar predominant ADCs vs. solid and invasive mucinous
ADCs.
ADC, adenocarcinoma; EGFR, epidermal growth factor receptor.
TABLE 7. Association of EGFR Mutation and EGFR/TTF-1
Expressions
Protein
Expression
EGFR Mutation Status
Total (%) pPositive (%) Negative (%)
EGFR
Positive (%) 101 (83.5) 82 (67.2) 183 (75.3) 0.003a
Negative (%) 20 (16.5) 40 (32.8) 60 (24.7)
243 (100)
TTF-1
Positive (%) 77 (92.8) 74 (69.2) 151 (79.4) 0.001a
Negative (%) 6 (7.2) 33 (30.8) 39 (20.6)
190 (100)
a 2 test.
EGFR, epidermal growth factor receptor; TTF-1, thyroid transcription factor-1.
TABLE 5. Relationship between EGFR Mutations and
Histologic Subtypes with and without Certain Components
in the Resected Specimens
Characteristics No. (%)
EGFR Mutation
Status
Ra p
Positive
(%)
Negative
(%)
ADC with BACb 117 (47.0) 80 (68.4) 37 (31.6) 0.25 0.001
ADC without BAC 132 (53.0) 58 (43.9) 74 (56.1)
ADC with papillaryb 60 (24.1) 41 (68.3) 19 (31.7) 0.15 0.02
ADC without papillary 189 (75.9) 97 (51.3) 92 (48.7)
ADC with acinar 228 (91.6) 125 (54.8) 103 (45.2) 0.04 0.3
ADC without acinar 21 (8.4) 13 (61.9) 8 (38.1)
ADC with M-BACc 16 (6.4) 2 (12.5) 14 (87.5) 0.23 0.001
ADC without M-BAC 233 (93.6) 136 (58.4) 97 (41.6)
ADC with micropapillary 140 (56.2) 76 (54.3) 64 (45.7) 0.03 0.39
ADC without
micropapillary
109 (43.8) 62 (56.9) 47 (43.1)
ADC with solidc 41 (16.5) 15 (36.6) 26 (63.4) 0.17 0.007
ADC without solid 208 (83.5) 123 (59.1) 85 (40.9)
a Spearman’s rank correlation coefficient.
b Tumors with BAC components vs. tumors with papillary components, p  1.0.
c Tumors with mucinous BAC components vs. tumors with solid components, p 
0.11.
EGFR, epidermal growth factor receptor; ADC, adenocarcinoma.
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tions in men who smoked have been reported from other
countries, the incidence did not exceed 20%.25–28 Although
men or smokers have not been considered as ideal candidates
for treatment with EGFR-TKIs, this result suggests that
EGFR mutation test should be performed in all the adeno-
carcinoma patients regardless of gender or smoking history.
Because EGFR mutation, not demographical features, is in-
dependently associated with a favorable prognosis of adeno-
carcinoma patients treated with EGFR-TKIs.29,30 If we want
to aim for a policy of no EGFR-mutated patients being left
behind, we must increase the number of candidates for the
EGFR mutation test as well as improve the sensitivity of the
test. Regarding sensitivity of the direct sequencing method
for EGFR mutation, microdissection is required for sufficient
tumor cell content. Our results showed similar incidence of
EGFR mutation according to the sampling types (surgically
resected tumor specimens versus small biopsy specimens).
Although tumor cells of the biopsy samples were smaller in
number than resected specimens, meticulous dissection per-
formed by pathologists seemed to minimize the contamina-
tion of nontumorous components.
Next, we tried to evaluate whether morphological fea-
tures reflect EGFR mutation status according to both 2004
WHO classification and new adenocarcinoma classification
by IASLC/ATS/ERS. When classifying the tumors based on
the two major components using the 2004 WHO classifica-
tion system, the EGFR mutations showed a clear distinction
according to the subtypes of adenocarcinomas. Mixed AB
and PA patterns showed more frequent EGFR mutations than
other types. However, the correlation between EGFR muta-
tions and histologic subtype of adenocarcinoma based on a
single predominant pattern according to new classification by
IASLC/ATS/ERS was not distinct. The new adenocarcinoma
classification system recommended as follows: “For invasive
adenocarcinomas, we suggest comprehensive histologic sub-
typing be used to assess histologic patterns semiquantitatively
in 5% increments, choosing a single predominant pattern.
Individual tumors are then classified according to the pre-
dominant pattern and the percentages of the subtypes are also
reported.”5 Therefore, we tried to correlate all the histologic
subtypes more than 5% in the tumor with EGFR mutation
status. We found that EGFR mutations were more frequently
observed in adenocarcinomas with BAC or papillary compo-
nents than in adenocarcinomas without the components and a
negative correlation between EGFR mutation and mucinous
BAC or solid components (Table 5). The results demon-
strated that there was a higher correlation between the mor-
phologic features and EGFR mutation status when classifying
the tumors based on mixed subtypes than the single predom-
inant pattern only. The histologic subtypes most often dis-
cussed in relationship to EGFR mutation were mixed subtype
adenocarcinomas with a BAC component. However, in our
study, tumors with papillary components showed a similar
mutation rate compared with the tumors with nonmucinous
BAC components. A similar frequency of EGFR mutations in
both BAC and papillary patterns could be explained by the
progression model that in adenocarcinomas with mixed sub-
types, the papillary pattern is usually regarded as a more
advanced form of the BAC.31,32 Further study is needed to
determine the biological similarities and differences between
tumors with papillary components and tumors with nonmu-
cinous BAC components. Regarding intratumoral heteroge-
neity of EGFR mutation status in the mixed subtype adeno-
carcinoma, we found same EGFR mutation status in the
different subtypes of the single tumor. This result suggests
that EGFR mutation, well-known oncogene driver mutation,
is acquired in an early step of peripheral pulmonary adeno-
carcinoma development and distributed throughout the tu-
mor.33 Although some studies have reported heterogeneous
distribution of the EGFR mutation in individual tumors,34,35 a
recent comprehensive study by Yatabe et al.33 suggested that
intratumoral heterogeneity of EGFR mutations is very rare,
and pseudoheterogeneity occurs due to a combination of
mutant allele-specific imbalance and heterogeneously distrib-
uted EGFR amplification.
In addition, our results indicated that EGFR overex-
pression was more frequently identified in the tumors with
EGFR mutations (83.5%, 101 of 121) than in those without
EGFR mutations (67.2%, 82 of 122, p  0.003). The results
suggest that EGFR mutation might be one of the causes of
EGFR protein overexpression. Our results also revealed that
TTF-1 overexpression tumors have more EGFR mutations.
TTF-1 can predict EGFR mutations.
In summary, the frequency of the EGFR gene mutation
is quite high among Korean patients with adenocarcinoma
(up to 68.5% in women, nonsmokers with adenocarcinoma)
and even in the men who smoked with adenocarcinoma
(29.7%). Mixed AB and PA patterns of lung adenocarcino-
mas with EGFR/TTF-1 protein expression are more fre-
quently associated with EGFR mutations. There was no
intratumoral heterogeneity of EGFR mutation status in the
mixed subtype of adenocarcinoma. It is necessary to test
EGFR mutational status in men as well as women and in
smokers as well as nonsmokers.
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